| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/27/2006 | US20060089309 Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| 04/27/2006 | US20060089308 Preconditioning human female; pregnancy; administering dehydroisoandrosterone and gonadotrophin |
| 04/27/2006 | US20060089307 Peptides that bind to the heparin binding domian of vegf and vegfr-2 |
| 04/27/2006 | US20060089306 New epilepsy mutations |
| 04/27/2006 | US20060089305 Compositions and methods for activating toll-like receptor 4 |
| 04/27/2006 | US20060089304 Treatment of psoriasis through down-regulation of the EGF-receptor with topically-applied EGF |
| 04/27/2006 | US20060089303 Cancer-testis antigens |
| 04/27/2006 | US20060089302 Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases |
| 04/27/2006 | US20060089301 Administering for example 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sarcosine]-4-(gamma hydroxymethylleucine)cyclosporin, or salts or hydrates thereof; improved nephrotoxicity and/or hepatotoxicity |
| 04/27/2006 | US20060089300 Macrocyclic peptides active against the hepatitis C virus |
| 04/27/2006 | US20060089299 Selective treatment of endothelial somatostatin receptors |
| 04/27/2006 | US20060089298 Novel substances k01-b0171 and process for producing the same |
| 04/27/2006 | US20060089297 Sperm specific lysozyme-like proteins |
| 04/27/2006 | US20060088938 Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants |
| 04/27/2006 | US20060088932 Truncated glycogen synthase kinase 3 crystallizable polypeptide; drug screening for Alzheimer's Disease treatments, antidiabetic and antiinflammatory agents |
| 04/27/2006 | US20060088915 A G protein-coupled receptor protein for the treatment of digestive diseases |
| 04/27/2006 | US20060088913 Mutation associated with epilepsy |
| 04/27/2006 | US20060088908 Mutiens of human neutrophil gelatinase-associated lipocalin and related proteins |
| 04/27/2006 | US20060088899 Combination chemotherapy with chlorotoxin |
| 04/27/2006 | US20060088897 Modulators |
| 04/27/2006 | US20060088884 Administering brain-derived neurotrophic factor in its native sequence to an oocyte; stimulation of oocyte maturation alleviates an infertility condition |
| 04/27/2006 | US20060088881 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules |
| 04/27/2006 | US20060088880 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 04/27/2006 | US20060088846 Methods to identify compounds useful for the treatment of proliferative and differentiative disorders |
| 04/27/2006 | US20060088835 Schizophrenia associated genes |
| 04/27/2006 | US20060088827 Diagnostic and therapeutic use of a voltage-gated ion channel scn2a for neurodegenerative diseases |
| 04/27/2006 | US20060088825 Human delta-n p73 molecules and uses thereof |
| 04/27/2006 | US20060088824 Used in assays to identify PAP-1/WIP-1 interaction inhibitors; West Nile virus (WNV) |
| 04/27/2006 | US20060088820 Detecting superantigen activity in a biological sample |
| 04/27/2006 | US20060088603 Compositions and methods for nutrition supplementation |
| 04/27/2006 | US20060088600 includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin |
| 04/27/2006 | US20060088595 Dispersant for sustained release preparations |
| 04/27/2006 | US20060088583 Artificial oxygen carrier containing preventive agents of metHb formation |
| 04/27/2006 | US20060088575 Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers |
| 04/27/2006 | US20060088565 Device having osteoinductive and osteoconductive properties |
| 04/27/2006 | US20060088558 Vitamin E TPGS fluid concentrate comprising a low percentage of water |
| 04/27/2006 | US20060088552 Method for inhibiting cell death, cell death inhibitor, and remedy for disease caused by cell death containing the cell death inhibitor |
| 04/27/2006 | US20060088548 Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| 04/27/2006 | US20060088543 Use of passive myostatin immunization |
| 04/27/2006 | US20060088541 Formulations that interact with and alter expression of epithelial cell tyrosine kinase |
| 04/27/2006 | US20060088540 Antagonists and methods for inhibiting angiogenesis |
| 04/27/2006 | US20060088537 Protein involved in cancer |
| 04/27/2006 | US20060088535 Method for enhancing long-term memory in a subject and uses thereof |
| 04/27/2006 | US20060088534 Human anti-factor ix/ixa antibodies |
| 04/27/2006 | US20060088533 Methods of treating inflammatory bowel disease |
| 04/27/2006 | US20060088532 Lymphatic and blood endothelial cell genes |
| 04/27/2006 | US20060088527 Lung tumor polynucleotides, polypeptides, fusion proteins, antigen presenting cells, T-cells and vaccines containing the polypeptide and an immunostimulant; genetic vaccines; improved early detection |
| 04/27/2006 | US20060088524 Tissue factor compositions and methods |
| 04/27/2006 | US20060088519 Malignant tumor-inhibiting preparation comprising Des A fibrin |
| 04/27/2006 | US20060088518 Stable thrombin composition |
| 04/27/2006 | US20060088517 Compounds and methods for treating seizure disorders |
| 04/27/2006 | US20060088516 Synthetic peptide combinations and methods of producing same |
| 04/27/2006 | US20060088515 Methods and devices for sustained in-vivo release of an active agent |
| 04/27/2006 | US20060088512 Treatment of T cell disorders |
| 04/27/2006 | US20060088511 Cancer therapy sensitizer |
| 04/27/2006 | US20060088502 Drug for reducing side effects in ribavirin interferon combination therapy |
| 04/27/2006 | US20060088501 Duffy antigen receptor for chemokines and use thereof |
| 04/27/2006 | US20060088499 Amphiphilic dendritic dipeptides & their self-assembly into helical pores |
| 04/27/2006 | US20060088497 Topical skin care composition |
| 04/27/2006 | US20060088481 Topical oral dosage forms containing bismuth compounds |
| 04/27/2006 | US20060088479 Particle formulation and its preparation |
| 04/27/2006 | US20060087736 Amyloid peptide inactivating enzyme to treat alzheimer's disease |
| 04/27/2006 | DE102004051025A1 Substituierte Nonadepsipeptide Substituted nonadepsipeptides |
| 04/27/2006 | DE102004051024A1 Heterocyclyl-substituierte Nonadepsipeptide Heterocyclyl-substituted nonadepsipeptides |
| 04/27/2006 | DE102004051014A1 Chemisch modifizierte Peptidanaloga Chemically modified peptide analogs |
| 04/27/2006 | DE102004050111A1 New active substances (e.g. 1-methyl-DL-tryptophan) are indolamine-2,3-dioxygenase enzyme inhibitors useful for the treatment of curative diseases such as cancer, local immune tolerance and/or suppressions and arteriosclerosis |
| 04/27/2006 | DE102004011663B4 Erythropoietin-Flüssigformulierung Erythropoietin liquid formulation |
| 04/27/2006 | CA2726144A1 Platelet-derived growth factor compositions and methods of use thereof |
| 04/27/2006 | CA2626774A1 Class iii slrp for the treatment of cancer |
| 04/27/2006 | CA2595669A1 Inhibition of tumor growth and metastasis by atf2-derived peptides |
| 04/27/2006 | CA2584915A1 Desoxo-nonadepsipeptides |
| 04/27/2006 | CA2584862A1 Autocrine growth factor receptors and methods |
| 04/27/2006 | CA2584515A1 Labeled compounds for proteasome inhibition |
| 04/27/2006 | CA2584512A1 Truncated fragments of alpha-synuclein in lewy body disease |
| 04/27/2006 | CA2584415A1 Topical treatment with ngf and dha in damaged corneas |
| 04/27/2006 | CA2584284A1 A method of reducing drug-induced adverse side effects in a patient |
| 04/27/2006 | CA2584263A1 Chemically modified peptide analogs |
| 04/27/2006 | CA2584069A1 Compositions containing lipase; protease and amylase for treating pancreatic insufficiency |
| 04/27/2006 | CA2584048A1 Multi-domain amphipathic helical peptides and methods of their use |
| 04/27/2006 | CA2584015A1 Fibronectin-modified ecm tissue graft constructs and methods for preparation and use thereof |
| 04/27/2006 | CA2583937A1 Chimeric protein |
| 04/27/2006 | CA2583900A1 Use of baff to treat sepsis |
| 04/27/2006 | CA2583666A1 Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| 04/27/2006 | CA2583399A1 Anti-angiogenic peptides and methods of use thereof |
| 04/27/2006 | CA2583138A1 Process for producing natural immunobiotic extract and uses thereof |
| 04/27/2006 | CA2582464A1 Antisense modulation of ptp1b expression |
| 04/27/2006 | CA2582462A1 Prion protein binding materials and methods of use |
| 04/27/2006 | CA2581278A1 Methods and materials for the inhibition of transplant rejection |
| 04/26/2006 | EP1650312A2 Functional assay of high-density lipoprotein |
| 04/26/2006 | EP1650307A2 Methods for making recombinant proteins using apoptosis inhibitors |
| 04/26/2006 | EP1650305A1 Mutants of the factor VII activating protease and methods for their detection |
| 04/26/2006 | EP1650304A2 Cloning and recombinant production of vespid venom phospholipase and immunological therapies based thereon |
| 04/26/2006 | EP1650224A1 Composition and method for repairing nerve damage and enhancing functional recovery of nerve |
| 04/26/2006 | EP1650221A2 Novel compounds |
| 04/26/2006 | EP1650220A2 Anti-VEGF antibodies |
| 04/26/2006 | EP1650219A1 Human toll homologues |
| 04/26/2006 | EP1650188A1 Treatment of tumors with RAR alpha selective retinoid compounds in combination with other anti-tumor agents |
| 04/26/2006 | EP1649871A1 Retroviral protease inhibitor combinations |
| 04/26/2006 | EP1649868A1 IL-12 as an adjuvant for Bordetella pertussis vaccines |
| 04/26/2006 | EP1649867A1 Stable thrombin composition |